UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed ...
UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...
Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Unity Biotechnology in a research ...
– Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan – – Succeeds Keith Leonard Who Will Continue as Chairman – SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) -- UNITY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results